Exelixis, Inc. (NASDAQ:EXEL) Holdings Decreased by Wellington Management Group LLP

Wellington Management Group LLP trimmed its position in Exelixis, Inc. (NASDAQ:EXEL) by 3.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 103,886 shares of the biotechnology company’s stock after selling 3,951 shares during the quarter. Wellington Management Group LLP’s holdings in Exelixis were worth $2,270,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in EXEL. Denali Advisors LLC increased its holdings in shares of Exelixis by 7,995.2% in the 3rd quarter. Denali Advisors LLC now owns 1,700 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 1,679 shares during the last quarter. Covestor Ltd increased its holdings in shares of Exelixis by 245.6% in the 1st quarter. Covestor Ltd now owns 1,676 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 1,191 shares during the last quarter. Fifth Third Bancorp increased its holdings in shares of Exelixis by 44.2% in the 3rd quarter. Fifth Third Bancorp now owns 1,970 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 604 shares during the last quarter. Ronald Blue Trust Inc. increased its holdings in shares of Exelixis by 87.2% in the 3rd quarter. Ronald Blue Trust Inc. now owns 2,552 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 1,189 shares during the last quarter. Finally, Natixis bought a new stake in shares of Exelixis in the 4th quarter valued at approximately $59,000. 85.27% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently commented on EXEL. Citigroup began coverage on Exelixis in a research note on Friday, December 15th. They set a “buy” rating and a $31.00 price objective for the company. TheStreet upgraded Exelixis from a “c+” rating to a “b-” rating in a research note on Monday, March 18th. JMP Securities restated a “market outperform” rating and set a $27.00 price objective on shares of Exelixis in a research note on Thursday, December 14th. Royal Bank of Canada upped their price objective on Exelixis from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. Finally, Barclays upped their price objective on Exelixis from $24.00 to $25.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 30th. Five equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $26.29.

Insider Activity

In related news, Director David Edward Johnson bought 190,000 shares of Exelixis stock in a transaction dated Wednesday, February 21st. The stock was acquired at an average cost of $20.70 per share, with a total value of $3,933,000.00. Following the completion of the acquisition, the director now directly owns 1,100,730 shares in the company, valued at approximately $22,785,111. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director David Edward Johnson bought 190,000 shares of Exelixis stock in a transaction dated Wednesday, February 21st. The stock was acquired at an average cost of $20.70 per share, with a total value of $3,933,000.00. Following the completion of the acquisition, the director now directly owns 1,100,730 shares in the company, valued at approximately $22,785,111. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Patrick J. Haley sold 47,020 shares of the company’s stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $21.45, for a total value of $1,008,579.00. Following the transaction, the executive vice president now directly owns 384,866 shares in the company, valued at $8,255,375.70. The disclosure for this sale can be found here. 2.90% of the stock is currently owned by company insiders.

Exelixis Stock Up 1.1 %

Shares of Exelixis stock opened at $23.86 on Thursday. The firm has a market cap of $7.23 billion, a price-to-earnings ratio of 37.28, a price-to-earnings-growth ratio of 0.62 and a beta of 0.53. The business has a fifty day simple moving average of $21.99 and a 200-day simple moving average of $21.97. Exelixis, Inc. has a fifty-two week low of $18.08 and a fifty-two week high of $24.34.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Tuesday, February 6th. The biotechnology company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.02. The business had revenue of $479.65 million during the quarter, compared to analyst estimates of $481.23 million. Exelixis had a return on equity of 8.57% and a net margin of 11.35%. Analysts anticipate that Exelixis, Inc. will post 1.22 earnings per share for the current fiscal year.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.